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Abstract
Background: Mitral regurgitation (MR) is one of the most common valvular diseases. Percu-
taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve 
repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir-
culating cardiac or inflammatory biomarkers and their association with individual functional, 
echocardiographic and clinical outcomes is poorly investigated.
Methods: A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 
41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu-
rich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive  
protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up 
of 3–6 months.
Results: Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596–5,722) to 
2,739 (IQR 1,440–4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline 
left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association 
class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third 
postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days.
Conclusions: Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up 
and changes in NT-proBNP levels are poor predictors of functional improvement or clinical 
outcome after MitraClip treatment. (Cardiol J 2016; 23, 4: 384–392)
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Introduction
Mitral regurgitation (MR) is the most common 
valve pathology found in the general population. 
Recently, percutaneous edge-to-edge mitral valve 
repair (PMVR) using the MitraClipTM system 
has emerged as a valuable alternative to surgery 
in high-risk patients with anatomical suitability 
for the device. First human trials, including the 
Endovascular Valve Edge-to-Edge Repair Study I 
(EVEREST), documented safety, reduction in MR, 
reverse left ventricular (LV) remodeling and im-
provements in quality of life [1, 2]. The EVEREST 
II randomized trial compared the safety and efficacy 
of the MitraClip device to mitral valve surgery in 
low-risk surgical candidates and demonstrated 
slightly lower efficacy but lower complication 
rates [3]. Moreover, retrospective studies suggest 
better outcomes after PMVR in high-risk patients 
compared to medical therapy [4].
Cardiac biomarkers have become integral 
elements in the clinical assessment and manage-
ment of patients with cardiac disease. Their levels 
usually correlate closely with disease severity 
and prognosis. B-type natriuretic peptide (BNP), 
a cardiac neurohormone, has vasodilating effects 
and relaxes vascular smooth muscle cells causing 
peripheral veno- and vasodilatation, and counter-
acting the high LV wall stress by reducing pre- and 
afterload. Especially in patients with heart failure 
(HF), this neurohormone is released in the pres-
ence of volume or pressure overload of the ventri-
cles in response to an increase in wall tension [5]. 
The 76-residue N-terminal fragment proBNP (NT-
-proBNP) has a longer half-life (120 min) and a more 
stable constitution than BNP, and therefore, it is 
less dependent on short fluctuations in volume 
status [6, 7]. PMVR with use of the MitraClip 
device can reduce LV wall stress by reducing MR 
and thereby induce reverse remodeling of both 
ventricles with reduction in diastolic and systolic 
LV volumes, however large studies assessing bio-
marker changes are scarce [8–11]. On the other 
hand, C-reactive protein (CRP) plays an important 
role in systemic response to inflammation. Several 
scientific reports have been published, highlighting 
the clinical use of CRP in diagnosis and prognosis of 
congestive HF [12]. An increase in CRP values in 
the early postoperative period after transcatheter 
aortic valve implantation (TAVI) was shown [13]. 
However, data on CRP changes after PMVR have 
been missing.
Thus, the aim of the present study was to 
evaluate the effect of PMVR on circulating cardiac 
or inflammatory biomarkers (NT-pro BNP and 
CRP), and their association with individual func-
tional, echocardiographic and clinical outcomes.
Methods
Study design
This study is a retrospective single-center 
observational clinical study of 144 patients with 
moderate-to-severe MR, who received PMVR us-
ing the MitraClip system at the University Heart 
Center Zurich. Patients were included in the pro-
spective MitraSwiss registry (MitraSwiss registry, 
KEK-ZH-Nr. 2010-0466), which is a national in-
vestigator-driven multicenter clinical registry that 
includes clinical, echocardiographic and biomarker 
follow-up of the patients. The study protocol was 
approved by the local institutional review board 
and all patients gave a written informed consent for 
their inclusion in the registry (MitraSwiss registry, 
KEK-ZH-Nr. 2010-0466).
Patient population
The severity of MR was assessed with two-
-dimensional (2D) echocardiography according to 
the recommendations of the American Society of 
Echocardiography [14]. Indications for PMVR in-
cluded patients with symptomatic MR (≥ 3+) due 
to degenerative or functional MR. High-surgical-
risk status defined by the European System for 
Cardiac Operative Risk Evaluation (EuroSCORE) 
was an additional criterion for PMVR. An inter-
disciplinary team of interventional cardiologists, 
echocardiographers, cardiac anesthetists, and 
cardiac surgeons from the University Heart Center 
Zurich selected patients for PMVR. Patients with 
rheumatic heart disease, endocarditis, a mitral 
valve orifice area £ 2.0 cm2, extensive prolapse 
of flail leaflets (prolapse width > 25 mm, flail gap 
> 20 mm) or patients who had any interventional 
or surgical procedure within 30 days were excluded 
from treatment [15].
Percutaneous mitral valve repair procedure
Percutaneous mitral valve repair with the 
MitraClip device (Abbott Vascular Structural 
Heart, Menlo Park, CA) was performed accord-
ing to standard technique described elsewhere 
[15] with echocardiographic (3D transesophageal 
echocardiography) and fluoroscopic guidance, and 
under general anesthesia. In the case of suboptimal 
reduction of MR, a second clip or third clip can be 
inserted on the lateral or medial side from the first 
clip. Acute procedural success was defined as suc-
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cessful MitraClip implantation with immediate MR 
reduction to grade 2+ or less by echocardiography.
Laboratory data
For this study, non-cardiac-specific and cardiac-
specific laboratory data were obtained by venous 
sampling through clinical follow-up at 3, 6 and 
12 months after PMVR in generally stable patients. 
NT-proBNP belongs to cardiac-specific biomarkers. 
Non-cardiac specific biomarkers were creatinine and 
CRP that was additionally measured in the early 
postoperative setting and during the same hospitali-
zation to assess early postoperative inflammatory 
response. Hematology values like hemoglobin and 
platelet count were also collected. Biomarker values 
from patients with clinical signs and symptoms of 
overt fluid retention or admitted for decompensated 
HF were rejected from the analysis.
Follow-up
Clinical follow-up was obtained from clinical 
records and by directly contacting the patients’ 
general physician. Clinical endpoints included 
death, reoperation of the mitral valve, hospitaliza-
tion for HF and heart transplantation. New York 
Heart Association (NYHA) functional class was 
obtained on clinical follow-up at 3–6 months.
Statistical analysis
All analyses were performed using SPSS ver-
sion 20.0 for Windows (SPSS, Inc., Chicago, Illinois). 
Quantitative data are expressed as mean ± standard 
deviation (SD) or median with interquartile range 
(IQR) where appropriate, and categorical data given 
in proportions and percentages. Statistical com-
parison of quantitative data was performed using 
a 2-tailed Wilcoxon signed rank test (Mann-Whitney 
U test) for paired samples or Kruskal-Wallis test for 
unrelated samples. Categorical data was compared 
with Fisher’s exact test. Results from different 
measurements were correlated using Spearman’s 
method. To analyze the follow-up data we obtained 
cumulative event rates using the Kaplan-Meier 
function. Event-free survival curves were plotted 
for a composite endpoint of death, HF re-hospital-
ization, reoperation and heart transplantation, and 
compared using the log-rank test. A p value < 0.05 
was considered statistically significant for all tests.
Results
Patient characteristics and procedural data
A group of 144 patients had baseline and 
follow-up biomarkers available and were included 
in this study. Baseline characteristics are shown 
in Table 1. The mean age was 75 ± 11 years and 
85 (59%) participants were male patients. Most 
patients had comorbidities including arterial hy-
pertension, hyperlipidemia, diabetes mellitus, or 
coronary artery disease. The mean LV ejection 
fraction was 46 ± 18%. Thirteen (9%) patients 
had previous valve surgery and 4 (3%) patients had 
previous vascular/thoracic surgery. One hundred 
and twenty-seven (88%) patients were in NYHA-
-functional class III–IV. Most patients had history 
of atrial fibrillation and impaired renal function.
The etiology and mechanism of MR is shown 
in Table 2. A functional mechanism was identified 
in 80 (56%) patients, while a degenerative etiology 
was seen in 55 (38%) patients.
Acute procedural success was achieved in 136 
(94%) patients. The majority (84; 58% patients) 
had 2 clips implanted, 37 (26%) patients had 1 clip, 
21 (15%) patients had 3 clips and in the rare case 
of 2 (1%) patients, there were 4 clips implanted. 
In-hospital death occurred in 6 (4%) patients.
Table 1. Patients baseline characteristics (n = 144).
Age [years] 75 ± 11
Male gender 85 (59%)
Body mass index [kg/m2] 25 ± 5
Clinical features:
Arterial hypertension 100 (69%)
Hyperlipidemia 60 (42%)
Diabetes mellitus 26 (18%)
Coronary artery disease: 64 (44%)
Previous MI 36 (25%)
Previous PCI 44 (31%)
Previous CABG 21 (15%)
Left ventricular ejection fraction [%] 46 ± 18
Previous valve surgery 13 (9%)
Previous vascular/thoracic surgery 4 (3%)
Atrial fibrillation 136 (94%)
COPD 21 (15%)
Previous stroke 14 (8%)
Impaired renal function 87 (60%)
Cancer 15 (10%)
NYHA functional class:
II 17 (12%)
III 99 (69%)
IV 28 (19%)
Data are given as mean ± standard deviation unless otherwise 
stated. CABG — coronary artery bypass grafting; COPD — chronic 
obstructive pulmonary disease; MI — myocardial infarction;  
NYHA — New York Heart Association; PCI — percutaneous 
coronary intervention
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Biomarker profiles
Biomarker laboratory data were available at 
baseline (before the procedure) and at 3–6-month 
follow-up. NT-proBNP data were available from 
91 patients, creatinine from 106 patients, creati-
nine-clearance from 82 patients, CRP from 73 pa-
tients, hemoglobin from 102 patients, and platelet 
counts from 98 patients, as shown in Table 3.
The median NT-proBNP level decreased slight-
ly after mitral valve clipping from 2,942 (IQR 1,596–
–5,722) to 2,739 (IQR 1,440–4,296) ng/L (Fig. 1). 
However, this difference fell short of statistical sig-
nificance (p = 0.21). Median change in pro-BNP lev-
els was –67 ng/L, however with a large variation of 
values ranging from –28,211 ng/L to +11,217 ng/L 
(Fig. 2). CRP levels decreased insignificantly 
from 4.3 (IQR 1.0–12.0) to 3.7 (1.2–10.0) mg/L 
(p = 0.25). There was no significant change of creati-
nine level (from 118 to 120 µmol/L; p = 0.72) or cre-
atinine-clearance (from 49 to 47 mL/min; p = 0.18). 
However, a slight but significant change in hemo-
globin level from 12.3 (IQR 10.8–13.4) to 12.4 
(11.3–13.6) g/dL was observed after the MitraClip 
procedure (p = 0.026).
NT-proBNP
There was no significant correlation of changes 
in NT-proBNP with baseline LV ejection fraction 
( r = –0.37, p = 0.74), LV end-diastolic volume 
(r = 0.049, p = 0.68), or LV end-systolic volume 
(r = 0.099, p = 0.41), however a weak, but sig-
Table 2. Etiology and mechanism of mitral  
regurgitation (n = 144).
Functional: 80 (56%)
Ischemic 35 (24%)
Non-ischemic 45 (32%)
Degenerative 55 (38%)
Mixed 9 (6%)
Data are given as absolute numbers and percentages
Table 3. Biochemical and hematological values before and after MitraClip implantation.
Parameter N Baseline 3–6 month P
NT-pro BNP [ng/L] 91 2942 (1596–5722) 2739 (1440–4296) 0.21
Creatinine [µmol/L] 106 118 (89–156) 120 (91–149) 0.72
Cr-clearance [mL/min] 82 49 (33–73) 47 (33–65) 0.18
C-reactive protein [mg/L] 73 4.3 (1.0–12.0) 3.7 (1.2–10.0) 0.25
Hemoglobin [g/dL] 102 12.3 (10.8–13.4) 12.4 (11.3–13.6) 0.026
Platelet count [×103/µL] 98 225 (181–270) 220 (169–258) 0.88
All values are given as median (interquartile range); NT-proBNP — N-terminal pro-B-type natriuretic peptide; Cr-clearance — creatinine-clearance
Figure 1. N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) serum levels at baseline and follow-up 
(3–6 months) after MitraClip implantation given as box-
plots with median value (black line), interquartile range 
(box), total range (whiskers) and outliers (circles).
Figure 2. Individual changes in N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) levels at baseline and 
follow-up after 3–6 months.
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nificant inverse correlation was found for base-
line pulmonary pressures (r = –0.32, p = 0.007) 
and a weak positive correlation with the change in 
pulmonary pressure from baseline to 3–6-month 
follow-up (r = 0.35, p = 0.006).
In patients with functional MR, median NT-
-proBNP level decreased from 3,195 (IQR 1,855–
–5,828) to 2,931 (IQR 1,608–4,787) ng/L after 
3–6-month follow-up (p = 0.445). No significant 
correlation was found for the presence of functional 
MR and baseline NT-proBNP level (r = –1.60, 
p = 0.110), although a significant correlation was 
found for follow-up NT-proBNP level (r = –2.313, 
p = 0.21).
On the other hand, changes in NT-proBNP 
did not correlate with NYHA functional class at 
follow-up (r = 0.13, p = 0.21). Figure 3 shows 
changes in NT-proBNP levels between baseline 
and follow-up (3–6 months) group based on NYHA 
functional class at follow-up. There was virtually 
no difference in median NT-proBNP changes in 
patients who were in NYHA class I, II, and III. Only 
in the worst group with NYHA class IV at follow-
up, NT-proBNP increased by 1,414 ng/L, however 
this change fell short of statistical significance 
compared to the other groups (p = 0.21).
Median follow-up was 724 days (IQR 372–
–1,073 days). A combined endpoint occurred in 
54 (59%) out of 91 the patients. Event rates for 
a combined endpoint were similar between patients 
in which NT-proBNP values increased after Mi-
traClip implantation compared to those who had 
a decrease in NT-proBNP (Fig. 4). Similarly, abso-
lute NT-proBNP values at follow-up appeared to 
be insignificant predictor of events (Fig. 5). Seven 
Figure 3. Changes in N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) serum levels compared to the 
follow-up New York Heart Association (NYHA) clas-
sification given as boxplots with median value (black 
line), interquartile range (box), total range (whiskers) 
and outliers (circles).
Figure 4. Survival of patients with an increase or de-
crease of N-terminal pro-B-type natriuretic peptide (NT-
-proBNP) is shown in the Kaplan-Meyer survival analysis. 
Combined endpoints were death, re-hospitalization for 
heart failure, reoperation and/or heart transplantation.
Figure 5. Survival of patients with absolute values of 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
at follow-up is shown as Kaplan-Meyer survival analy-
sis. Combined endpoints for follow-up were death, re-
hospitalization for heart failure, reoperation and/or heart 
transplantation.
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patients had NT-proBNP baseline levels > 10,000 
ng/L of whom 4 patients reached a combined end-
point (1 death and 3 re-hospitalizations for HF).
CRP
Long-term CRP changes. CRP levels from 
73 patients indicate numerical albeit statistically in-
significant (p = 0.25) decrease after PMVR (Fig. 6). 
Median change in CRP levels after MitraClip pro-
cedure was –0.1 mg/L with a variation of values 
ranging from –92 mg/L to +37.4 mg/L.
Short-term inflammatory response. Early 
postoperative CRP levels were available in 93 pa-
tients (Fig. 7). Median baseline CRP on the day 
of the PMVR procedure was 5.6 mg/L (IQR 1.1– 
–19.0 mg/L) and increased over the ensuing 
3 postoperative days reaching a peak on the 
3rd postoperative day at 34.0 mg/L (IQR 18.5– 
–58.5 mg/L). Thereafter, CRP levels regressed 
albeit at a lower rate with a median CRP of 
18.5 mg/L (IQR 8.1–33.0 mg/L) at day 7.
Discussion
In our retrospective study of 144 patients with 
severe MR undergoing PMVR with the MitraClip 
system, we observed no statistically significant 
change in circulating biomarkers on long-term 
follow-up 3–6 months after successful PMVR. 
Median NT-proBNP decreased insignificantly and 
NT-proBNP changes did not correlate with either 
baseline LV ejection fraction or LV dimensions, nor 
NYHA class on follow-up, or with clinical events 
on follow-up. CRP levels reached a peak on the 
3rd postoperative day with a subsequent slow de-
crease over the ensuing days, and on follow-up, 
we showed numerical but insignificant decrease.
NT-proBNP serum levels reflect cardiac wall 
stress and higher concentrations can be measured 
in patients with HF [5]. MitraClip implantation can 
reduce LV wall stress by reducing MR and thereby 
induce reverse remodeling of both ventricles with 
reduction in diastolic and systolic LV volumes [8]. 
We assumed that NT-proBNP levels would sig-
Figure 6. C-reactive protein (CRP) serum levels at base-
line and follow-up (3–6 months) after MitraClip implan-
tation given as boxplots with median value (black line), 
interquartile range (box), and total range (whiskers).
Figure 7. C-reactive protein (CRP)-course in the early postoperative period after percutaneous mitral valve repair with 
MitraClip as median value (bold blue line) with interquartile range (whiskers).
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nificantly decrease at 3–6-month follow-up when 
reverse remodeling starts to have an impact on the 
ventricles. However, our results show an insignifi-
cant reduction of NT-proBNP, similarly to a previ-
ously published sub-study from our group [16]. 
Interestingly, changes in NT-proBNP were similar 
in patients with functional MR versus degenera-
tive MR. We expected changes in NT-proBNP to 
be less pronounced in patients with functional 
MR, since preload depends less on MR only, but 
also on the reduced contractility of the diseased 
myocardium. In addition, changes in NT-proBNP 
showed only a weak correlation with baseline 
pulmonary pressures and changes in pulmonary 
pressure after PMVR. Moreover, changes in NT-
-proBNP could not be predicted by baseline LV 
function or volumes. Changes in NT-proBNP were 
also a poor predictor for improvement of patients’ 
HF symptoms after MitraClip implantation. Only 
patients with the poorest outcomes (NYHA class 
IV on follow-up) showed invariably an increase 
of NT-proBNP by 1,000 ng/L or more. However, 
similar postoperative NT-proBNP changes were 
observed for patients with follow-up NYHA class I, 
II, or III, respectively. Similarly, clinical event rates 
(death, re-hospitalization for HF, reoperation and/ 
/or heart transplantation) were similar in patients 
who decreased their NT-proBNP value compared 
to those in whom it increased.
In surgical mitral valve repair, there is an asso-
ciation between significant decrease of NT-proBNP 
levels and an improvement in HF symptoms [17]. 
Our data could not confirm this association, al-
though generally there was a significant decrease 
in NYHA class in 63 (70%) patients.
Thus, we conclude that serum NT-proBNP 
is marginally beneficial in the follow-up of HF 
patients after MitraClip implantation and should 
not be routinely performed to assess the clini-
cal success of MitraClip implantation. A possible 
explanation of these findings lies in the underly-
ing pathophysiological changes observed in the 
LV after PMVR — successful PMVR results in 
a significant decrease in LV preload from remov-
ing the regurgitant blood volume. These changes, 
however, are counteracted by a significant increase 
in afterload, which occurs from removing the low 
impedance pathway to LV systolic unloading. Since 
both, afterload and preload, appear to change to 
the same extent after PMVR, the net effect on LV 
wall stress (which consists of diastolic and systolic 
wall stress) reaches equipoise, and therefore NT-
-proBNP values do not change significantly [18]. 
Nonetheless, other hemodynamic studies have 
proven that despite these changes in afterload, 
PMVR improves hemodynamic profiles through 
an increase in cardiac index and a decrease in pul-
monary pressures [15, 18].
Our results are somewhat at variance with 
NT-proBNP data reported in other studies, where 
a statistical significant decrease of NT-proBNP 
was reported [8–11]. Franzen et al. [11, 19] report 
a significant reduction in NT-proBNP values from 
4,900 ng/L to 3,300 ng/L in 18 patients with end-
stage HF. The PERMIT-CARE registry of non-
responders to cardiac resynchronization therapy 
(CRT) reports a baseline NT-proBNP of 3,702 ng/L 
but no biomarker follow-up was obtained in this 
registry [20]. A very similar study by Seifert et 
al. [10] in 42 CRT non-responders, reported a re-
duction in NT-proBNP levels from 3,923 ng/L to 
2,636 ng/L. Neuss et al. [9] followed 111 patients 
with congestive HF (73% functional MR, ejection 
fraction 41%) after PMVR and found a significant 
decrease in NT-proBNP from 3,452 ng/L to ap-
proximately 2,500 ng/L. However, none of the large 
registries (ACCESS-Europe, TRAMI, Pilot Euro-
pean Sentinel, EVEREST High Risk Registry, and 
REALISM) included NT-proBNP as an endpoint.
Most studies with NT-proBNP data had 
a smaller number of patients (< 35 patients) than 
our study, except of Neuss et al. [9] with 111 pa-
tients. Additionally, baseline NT-proBNP values 
in the aforementioned trials were higher than in 
our patients, which may explain the significant 
reduction observed in those trials, and may make 
these trials more susceptible to statistical “regres-
sion to the mean” bias. In contrast, our patients 
had slightly lower baseline NT-proBNP values 
and higher ejection fraction, which may have 
blunted any potential effect of PMVR on changes in 
NT-proBNP.
Regarding survival analysis, previous studies 
showed that higher NT-proBNP levels had signifi-
cantly poorer outcomes [9]. Our survival analysis 
could not confirm this statement. However, for 
patients at the extreme high range of NT-proBNP 
values with over > 10,000 ng/L it was more likely 
to have a poorer outcome. Although our study failed 
to prove NT-proBNP as a reliable biomarker, we 
recognize the potential advantages of additional 
serial measurements of NT-proBNP during longer-
term follow-up. Nevertheless, the clinical condition 
of the patient and echocardiographic information 
seem to be more reliable parameters for follow-up 
shortly after MitraClip implantation.
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Similar to NT-proBNP, there was a numerical 
however non-statistical decrease of CRP level 
at long-term follow-up after 3–6 months. During 
the short-time follow-up, systemic inflammation 
reached a maximum on day 3 (median CRP level 
of 34.0 mg/L; IQR 18.5–58.5 mg/L) and decreased 
after a few days. CRP changes following MitraClip 
have been poorly investigated, in contrary to TAVI, 
where an increase in CRP values in the early post-
operative period was shown, and was correlated 
with poorer outcome [13]. In comparison to TAVI, 
increases in post-procedural CRP levels after 
MitraClip implantation are 2–3 times lower [13]. 
The TAVI procedure is accomplished in majority of 
cases by retrograde transfemoral approach to the 
aortic valve, where a prosthetic stent expands the 
annulus of the aortic valve, thereby compressing 
the native valve [21]. However, PMVR with the 
MitraClip system, besides the transseptal puncture 
and the introduction of the 22 F steerable guide 
catheter, induces only a small local inflammation 
from smaller punctures and clip attachment on 
smaller parts of the leaflets, thus it is less traumatic 
and has fewer serious complications. This may 
explain the much smaller increase in CRP values 
in the early postoperative period.
Limitations of the study
The retrospective design of the study may be 
perceived as a limitation. As a consequence, there 
was no uniform prospective protocol for venous 
blood sampling available, and therefore biomarker 
documentation and follow-up was incomplete 
throughout our study population. Additionally, we 
could not obtain more sophisticated biomarkers 
of inflammation, such as interleukins or tumor-
necrosis factor.
The limited sample size is another important 
limitation of this study. It may well be that numeri-
cal differences observed in our sample would reach 
statistical significance if the sample was increased 
to several hundreds of patients. Nonetheless, 
statistical significance does not necessarily beget 
clinical significance. Therefore, we doubt that we 
would come to a very different clinical conclusion 
by a largely increased study population.
B-type natriuretic peptide values have a short 
half-life and their serum concentration varies ac-
cording to volume-loaded conditions. This is why 
we chose NT-proBNP, which has a longer half-life 
and is less susceptible to short-term changes in 
volume conditions. Additionally, biomarker values 
were excluded if the patient was admitted to the 
hospital for HF or had obvious clinical signs of new 
fluid retention. However, despite these theoretical 
advantages of NT-proBNP, some marginal effects of 
volume status on serum levels cannot be denied. 
This study assessed only follow-up data at 3–6 
months due to lack of laboratory data. NT-proBNP 
values after a longer follow-up may show different 
results, because reverse remodeling of the LV is 
an ongoing process.
Conclusions
Despite successful PMVR, NT-proBNP and 
CRP levels remain fairly unchanged on follow-up 
and changes in NT-proBNP are poor predictors of 
functional improvement or clinical outcome after 
MitraClip treatment.
We conclude that serum NT-proBNP has 
a limited clinical value in the follow-up of HF patients 
after MitraClip implantation. Other parameters, 
such as clinical and echocardiographic assessment 
should be prioritized over biomarkers to assess the 
long-term success of MitraClip implantation.
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